These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 24741770)

  • 1. A review on the cause-effect relationship between oxidative stress and toxic proteins in the pathogenesis of neurodegenerative diseases.
    Borza LR
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(1):19-27. PubMed ID: 24741770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurodegeneration. Could they all be prion diseases?
    Miller G
    Science; 2009 Dec; 326(5958):1337-9. PubMed ID: 19965731
    [No Abstract]   [Full Text] [Related]  

  • 3. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
    Ciechanover A; Kwon YT
    Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of proteins in neurodegenerative disease].
    Szwed A; Miłowska K
    Postepy Hig Med Dosw (Online); 2012 Apr; 66():187-95. PubMed ID: 22706103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress-enhanced SUMOylation and aggregation of ataxin-1: Implication of JNK pathway.
    Ryu J; Cho S; Park BC; Lee DH
    Biochem Biophys Res Commun; 2010 Mar; 393(2):280-5. PubMed ID: 20132795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein and neurodegenerative diseases.
    Goedert M
    Nat Rev Neurosci; 2001 Jul; 2(7):492-501. PubMed ID: 11433374
    [No Abstract]   [Full Text] [Related]  

  • 7. SUMO and its role in human diseases.
    Sarge KD; Park-Sarge OK
    Int Rev Cell Mol Biol; 2011; 288():167-83. PubMed ID: 21482412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins.
    Butterfield DA; Kanski J
    Mech Ageing Dev; 2001 Jul; 122(9):945-62. PubMed ID: 11348660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase in neurodegenerative processes and the role of low molecular weight compounds in counteracting its aggregation and nuclear translocation.
    Gerszon J; Rodacka A
    Ageing Res Rev; 2018 Dec; 48():21-31. PubMed ID: 30254002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases.
    Tabner BJ; Turnbull S; El-Agnaf O; Allsop D
    Curr Top Med Chem; 2001 Dec; 1(6):507-17. PubMed ID: 11895127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.
    Choonara YE; Pillay V; Du Toit LC; Modi G; Naidoo D; Ndesendo VMK; Sibambo SR
    Int J Mol Sci; 2009 Jun; 10(6):2510-2557. PubMed ID: 19582217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNAi silencing in mouse models of neurodegenerative diseases.
    Farah MH
    Curr Drug Deliv; 2007 Apr; 4(2):161-7. PubMed ID: 17456035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-onset neurodegenerative diseases--the role of protein insolubility.
    Johnson WG
    J Anat; 2000 May; 196 ( Pt 4)(Pt 4):609-16. PubMed ID: 10923991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of polyglutamine proteins on nuclear organization and artificial reporter splicing.
    Sun J; Xu H; Negi S; Subramony SH; Hebert MD
    J Neurosci Res; 2007 Aug; 85(11):2306-17. PubMed ID: 17526020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases.
    Ghosh S; Feany MB
    Hum Mol Genet; 2004 Sep; 13(18):2011-8. PubMed ID: 15254017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metals, oxidative stress and neurodegenerative disorders.
    Jomova K; Vondrakova D; Lawson M; Valko M
    Mol Cell Biochem; 2010 Dec; 345(1-2):91-104. PubMed ID: 20730621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein folding diseases and neurodegeneration: lessons learned from yeast.
    Winderickx J; Delay C; De Vos A; Klinger H; Pellens K; Vanhelmont T; Van Leuven F; Zabrocki P
    Biochim Biophys Acta; 2008 Jul; 1783(7):1381-95. PubMed ID: 18298958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemistry and biochemistry of oxidative stress in neurodegenerative disease.
    Sayre LM; Smith MA; Perry G
    Curr Med Chem; 2001 Jun; 8(7):721-38. PubMed ID: 11375746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases.
    Melki R
    J Parkinsons Dis; 2015; 5(2):217-27. PubMed ID: 25757830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies.
    Chalmers KA; Love S
    J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.